Despite a sharp stock decline, Insulet’s latest quarterly results reveal a narrow setback in US Type 2 diabetes retention, with future growth opportunities intact through product innovation and newly approved uses of Omnipod 5.
Insulet is being treated by the market as a damaged story, but the latest figures suggest the problem is narrower than the sell-off implies. The insulin pump maker reported second-quarter revenue of $801.7m, ahead of expectations, and the company said it still sees strong long-term growth as it works through a setback in its US Type 2 diabetes business. Insulet’s shares have fallen sharply this year, yet the underlying business continues to show demand, product differentiation and margin strength.
The immediate concern is not a collapse in demand but a retention issue among newer Type 2 users. Insulet has been winning patients and doctors, but too many of those users were not staying with the device through the first 90 days. Management has acknowledged the miss and is changing follow-up, support and incentives to focus more on keeping patients engaged after start-up. That distinction matters: the company is not facing evidence of market-share loss or pricing pressure, but rather a fixable onboarding problem.
The opportunity in Type 2 diabetes remains central to the bull case. Insulet won clearance in 2024 to use Omnipod 5 in people with Type 2 diabetes, opening access to millions of potential users in the United States. The company has also pointed to encouraging work in advanced automation, including a fully closed-loop system for adults with Type 2 diabetes. In a feasibility study it presented this year, the system achieved 68% time in range without boluses, a sign that the platform still has room to widen its clinical appeal.
That matters because the broader narrative around GLP-1 drugs may have been overdone. Investors initially worried that weight-loss medicines would shrink the market for insulin delivery devices, but that view was too simplistic. For many people with Type 2 diabetes, GLP-1 therapy is more likely to bring them deeper into treatment pathways than to eliminate the need for insulin altogether. If anything, the issue for Insulet is execution, not demand destruction.
The stock’s appeal to patient investors rests on valuation as much as on strategy. After the post-earnings drop, Insulet has been trading at a steep discount to its own history and to other fast-growing medical technology names. Analyst views remain mixed, with some firms cutting targets after the guidance reset, while others still see room for recovery if retention improves and international momentum continues. The next few quarters will be crucial: if management shows that the Type 2 issue is being addressed, the shares could re-rate long before the company has fully returned to its former growth trajectory.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
